These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21712425)

  • 1. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
    Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
    Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
    Cao X; Mitra AK; Pounds S; Crews KR; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    Pharmacogenomics; 2013 Sep; 14(12):1449-66. PubMed ID: 24024897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.
    Galmarini CM; Graham K; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Mackey JR; Dumontet C
    Blood; 2001 Sep; 98(6):1922-6. PubMed ID: 11535530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic factors influencing cytarabine therapy.
    Lamba JK
    Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.
    Hartford CM; Duan S; Delaney SM; Mi S; Kistner EO; Lamba JK; Huang RS; Dolan ME
    Blood; 2009 Mar; 113(10):2145-53. PubMed ID: 19109566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
    Aksoy P; Zhu MJ; Kalari KR; Moon I; Pelleymounter LL; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM; Wang L
    Pharmacogenet Genomics; 2009 Aug; 19(8):567-76. PubMed ID: 19623099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
    Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
    Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
    Jordheim LP; Nguyen-Dumont T; Thomas X; Dumontet C; Tavtigian SV
    Drug Metab Dispos; 2008 Dec; 36(12):2419-23. PubMed ID: 18775979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
    Cheong HS; Koh Y; Ahn KS; Lee C; Shin HD; Yoon SS
    Pharmacogenet Genomics; 2014 Sep; 24(9):436-41. PubMed ID: 25000516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms of resistance to cytarabine in AML patients.
    Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
    Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
    Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
    Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.
    Yin B; Kogan SC; Dickins RA; Lowe SW; Largaespada DA
    Exp Hematol; 2006 May; 34(5):631-41. PubMed ID: 16647569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.
    Galmarini CM; Cros E; Thomas X; Jordheim L; Dumontet C
    Haematologica; 2005 Dec; 90(12):1699-701. PubMed ID: 16330448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
    Suzuki K; Sugawara T; Oyake T; Uchiyama T; Aoki Y; Tsukushi Y; Onodera S; Ito S; Murai K; Ishida Y
    Leuk Res; 2007 Oct; 31(10):1343-9. PubMed ID: 17350683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.
    Jiang C; Yang W; Moriyama T; Liu C; Smith C; Yang W; Qian M; Li Z; Tulstrup M; Schmiegelow K; Crews KR; Zhang H; Pui CH; Evans W; Relling M; Bhatia S; Yang JJ
    Clin Pharmacol Ther; 2021 Jun; 109(6):1538-1545. PubMed ID: 33124053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
    Díaz-Santa J; Rodríguez-Romanos R; Coll R; Osca G; Pratcorona M; González-Bártulos M; Garrido A; Angona A; Talarn C; Tormo M; Arnan M; Vives S; Salamero O; Tuset E; Lloveras N; Díez I; Zamora L; Bargay J; Sampol A; Cruz D; Vila J; Sitges M; Garcia A; Vall-Llovera F; Esteve J; Sierra J; Gallardo D;
    Eur J Haematol; 2022 Dec; 109(6):755-764. PubMed ID: 36063368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.